Santhera Pharmaceuticals Holding AG - Asset Resilience Ratio

Latest as of December 2023: 27.70%

Santhera Pharmaceuticals Holding AG (SANN) has an Asset Resilience Ratio of 27.70% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SANN working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CHF30.37 Million

≈ $38.40 Million USD Cash + Short-term Investments

Total Assets

CHF109.63 Million

≈ $138.60 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2024)

This chart shows how Santhera Pharmaceuticals Holding AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Santhera Pharmaceuticals Holding AG (SANN) total assets.

Liquid Assets Composition Over Time

This chart breaks down Santhera Pharmaceuticals Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Santhera Pharmaceuticals Holding AG (SANN) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF30.37 Million	27.7%
Short-term Investments	CHF0.00	0%
Total Liquid Assets	CHF30.37 Million	27.70%

Asset Resilience Insights

Very High Liquidity: Santhera Pharmaceuticals Holding AG maintains exceptional liquid asset reserves at 27.70% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Santhera Pharmaceuticals Holding AG Industry Peers by Asset Resilience Ratio

Compare Santhera Pharmaceuticals Holding AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Santhera Pharmaceuticals Holding AG (2006–2024)

The table below shows the annual Asset Resilience Ratio data for Santhera Pharmaceuticals Holding AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	14.82%	CHF22.59 Million ≈ $28.57 Million	CHF152.49 Million ≈ $192.79 Million	-5.11pp
2023-12-31	19.92%	CHF21.84 Million ≈ $27.62 Million	CHF109.63 Million ≈ $138.60 Million	-3.35pp
2021-12-31	23.28%	CHF21.21 Million ≈ $26.81 Million	CHF91.12 Million ≈ $115.20 Million	+24.64pp
2018-12-31	-1.36%	CHF-1.50 Million ≈ $-1.90 Million	CHF110.29 Million ≈ $139.44 Million	-13.21pp
2017-12-31	11.85%	CHF13.01 Million ≈ $16.45 Million	CHF109.78 Million ≈ $138.79 Million	-43.02pp
2016-12-31	54.87%	CHF49.81 Million ≈ $62.98 Million	CHF90.79 Million ≈ $114.79 Million	+54.81pp
2007-12-31	0.06%	CHF81.00K ≈ $102.41K	CHF144.18 Million ≈ $182.28 Million	-0.11pp
2006-12-31	0.16%	CHF263.00K ≈ $332.50K	CHF162.39 Million ≈ $205.31 Million	--

pp = percentage points

About Santhera Pharmaceuticals Holding AG

SW:SANN Switzerland Biotechnology

Market Cap

$286.57 Million

CHF226.67 Million CHF

Market Cap Rank

#15866 Global

#170 in Switzerland

Share Price

CHF15.94

Change (1 day)

+1.27%

52-Week Range

CHF9.58 - CHF18.54

All Time High

CHF1070.00